Thrivent Financial for Lutherans Sells 38,212 Shares of Illumina, Inc. $ILMN

Thrivent Financial for Lutherans trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 690,543 shares of the life sciences company’s stock after selling 38,212 shares during the period. Thrivent Financial for Lutherans’ holdings in Illumina were worth $65,581,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ILMN. Parkside Financial Bank & Trust raised its stake in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Illumina in the 3rd quarter valued at approximately $29,000. Cullen Frost Bankers Inc. purchased a new stake in Illumina during the 2nd quarter worth approximately $41,000. NewSquare Capital LLC raised its holdings in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after buying an additional 369 shares during the last quarter. Finally, Mather Group LLC. purchased a new stake in shares of Illumina during the third quarter valued at $46,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Guggenheim lifted their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. UBS Group lifted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Evercore ISI restated an “outperform” rating and set a $155.00 price target on shares of Illumina in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $127.18.

Insiders Place Their Bets

In other news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is currently owned by corporate insiders.

Illumina Price Performance

Illumina stock opened at $144.81 on Monday. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The company’s 50 day simple moving average is $138.08 and its 200-day simple moving average is $115.16. The company has a market capitalization of $22.13 billion, a price-to-earnings ratio of 32.47, a price-to-earnings-growth ratio of 2.40 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up .4% compared to the same quarter last year. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.